One out of 6 adults in the US (33 millions) and one out of 10 worldwide (546 millions) are affected by overactive bladder (OAB). Despite the high economic cost ($82 billions by 2020), treatment response to OAB remains suboptimal. Using data from over 1 million men and women, we will identify biological (eg, genomics, ethnicity, medical history), behavioral (lifestyle), and metabolic factors (eg, metabolic syndrome, obesity) that predict response vs. non-response to clinical OAB treatments.
Idea No. 704